Effects of Tadalafil on LMR and MHR in Patients With ED

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

62 participants

Study Classification

OBSERVATIONAL

Study Start Date

2019-02-14

Study Completion Date

2019-04-05

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The aim of the study was to investigate whether daily 5 mg tadalafil over eight weeks affects to Lymphocyte/Monocyte ratio (LMR) and Monocyte/High-Density Lipoprotein ratio (MHR) in patients with erectile dysfunction (ED).

Thirty-one patients with organic ED and 31 healthy controls between July 2017 and November 2018 were included in this retrospective study. To avoid bias, the patients were randomly selected and the controls were also incorporated consecutively. The presence of ED was determined according to the International Erectile Function Index-5 (IIEF-5). The patients and the controls were evaluated in terms of IIEF-5, complete blood count, serum biochemistry, LMR, and MHR.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Comparing The Effect of Tadalafil 5 mg/Day to Sildenafil 25 mg/Day on Neutrophil-Lymphocyte and Platelet-Lymphocyte Ratios in Erectile Dysfunction Patients; and Comparison of Clinical Response

NCT05466695

Erectile Dysfunction and Neutrophil Lymphocyte Ratio

UNKNOWN EARLY_PHASE1

Effect of Tadalafil Once a Day in Men With Erectile Dysfunction

NCT00836693

Erectile Dysfunction

COMPLETED PHASE3

A Study to Evaluate the Efficacy and Safety of 2.5mg and 5mg Tadalafil Given Once a Day to Men With Erectile Dysfunction

NCT00381732

Erectile Dysfunction

COMPLETED PHASE3

Determine If the Stress That Comes With Not Developing an Erection Affects Tadalafil Effects

NCT00547599

Impotence

COMPLETED PHASE4

Effect of Tadalafil on the Quality of Life and Sexual Life in Erectile Dysfunction

NCT00422578

Impotence Erectile Dysfunction

COMPLETED PHASE4

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

The medical records of the heterosexual men treated with the diagnosis of organic ED in the Urology department of a private hospital between July 2017 and October 2018 were evaluated retrospectively. The number of samples to be included in the study was determined by the help of the computer-assisted power analysis. Random sampling was performed from all cohorts of patients with ED. Thirty-one male patients between the ages of 39-65 with organic erectile dysfunction more than one year and treated with OAD 5 mg dose of tadalafil for eight weeks were selected as the treatment group (group T)The patients in group T have been assessed both before (T1) and after (T2) the treatment.

Between the ages of 39-65, thirty-one healthy men who were admitted to the internal medicine outpatient clinic for their annual follow-up were selected consecutively and the control group (group C) was formed. All subjects in the control group were sexually active men with regular monogamous heterosexual relationships during the last one year.

.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Erectile Dysfunction Inflammation

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

CASE_CONTROL

Study Time Perspective

RETROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Group T

31 Patients with ED who receiving 5 mg/day of Tadalafil for 8 weeks.

Tadalafil 5mg tablet

Intervention Type DRUG

Once-a-day 5 mg dose of tadalafil for 8 weeks

Group C

Thirty-one healthy men who were admitted to the internal medicine outpatient clinic for their annual follow-up

No interventions assigned to this group

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Tadalafil 5mg tablet

Once-a-day 5 mg dose of tadalafil for 8 weeks

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

phosphodiesterase type 5 (PDE5) inhibitor

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* 39-65 years old men with ED
* 39-65 years old, haelthy men
* Patients that have received 5 mg tadalafil/day for 8 weeks
* Patients with informed consent forms
* Patients with no missing variables

Exclusion Criteria

* Patients with systemic autoimmune and inflammatory disease,
* congestive heart failure,
* chronic renal failure, and chronic hepatobiliary disease,
* chronic lung disease, and thyroid dysfunction,
* patients with acute infection,
* patients with neurological deficits,
* metabolic syndrome and malignancy
* Patients with a history of prostate, penile or pelvic surgery or radiotherapy,,
* patients receiving anticoagulant, beta-blocker, antidepressants and antipsychotics, hormonal therapy,
* patients with alcohol and smoking

Minimum Eligible Age

39 Years

Maximum Eligible Age

65 Years

Eligible Sex

MALE

Accepts Healthy Volunteers

Yes